{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:37:02Z","timestamp":1784191022867,"version":"3.55.0"},"reference-count":72,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:title>This Policy Statement was retired July 2010.<\/jats:title>\n               <jats:p>Since licensure in 1995 of a hepatitis A vaccine, the Centers for Disease Control and Prevention and the American Academy of Pediatrics have been implementing an incremental hepatitis A immunization strategy for children. In 1996, children living in populations with the highest rates of disease were targeted for immunization, and in 1999 the program was expanded to immunization of children 2 years and older living in states and counties with rates of hepatitis A that historically have been higher than the national average. The 1999 program has been successful; the current rate of hepatitis A is the lowest ever reported in the United States. Regional, ethnic, and racial differences in the incidence of hepatitis A have been eliminated. The incidence of hepatitis A in adults in immunizing states has decreased significantly, suggesting a strong herd-immunity effect associated with immunization. In 2005, the US Food and Drug Administration changed the youngest approved age of administration of hepatitis A vaccine from 24 to 12 months of age, which facilitated incorporation of the vaccine into the recommended childhood immunization schedule. As the next step in the implementation of the incremental vaccine immunization strategy, the American Academy of Pediatrics now recommends routine administration of a Food and Drug Administration\u2013licensed hepatitis A vaccine to all children 12 to 23 months of age in all states according to a Centers for Disease Control and Prevention\u2013approved immunization schedule. Available data suggest that hepatitis A vaccine can be coadministered with other childhood vaccines without decreasing immunogenicity. Hepatitis A vaccines have proven to be extremely safe. In prelicensure clinical trials of both Havrix (GlaxoSmithKline, Rixensart, Belgium) and Vaqta (Merck &amp; Co Inc, Whitehouse Station, NJ), adverse events were uncommon and mild when they occurred, with resolution typically in less than 1 day. Hepatitis A vaccine is contraindicated in people with a history of severe allergic reaction to a previous dose of hepatitis A vaccine or to a vaccine component. Because the hepatitis A vaccine is an inactivated product, no special precautions are needed for administration to people who are immunocompromised. No data exist about administration of the hepatitis A vaccine to pregnant women, but because it is not a live vaccine, the risk to mother and fetus should be extremely low to nonexistent.<\/jats:p>","DOI":"10.1542\/peds.2007-1088","type":"journal-article","created":{"date-parts":[[2007,7,2]],"date-time":"2007-07-02T16:35:25Z","timestamp":1183394125000},"page":"189-199","source":"Crossref","is-referenced-by-count":52,"title":["Hepatitis A Vaccine Recommendations"],"prefix":"10.1542","volume":"120","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,7,1]]},"reference":[{"key":"2023092514111140500_R1","doi-asserted-by":"crossref","unstructured":"Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics.\u20082002;109:839\u2013845","DOI":"10.1542\/peds.109.5.839"},{"key":"2023092514111140500_R2","unstructured":"Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46:588]. MMWR Recomm Rep.\u20081996;45(RR-15):1\u201330"},{"key":"2023092514111140500_R3","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics.\u20081996;98:1207\u20131215","DOI":"10.1542\/peds.98.6.1207"},{"key":"2023092514111140500_R4","unstructured":"Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20081999;48(RR-12):1\u201337"},{"key":"2023092514111140500_R5","doi-asserted-by":"crossref","unstructured":"Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA.\u20082005;294:194\u2013201","DOI":"10.1001\/jama.294.2.194"},{"key":"2023092514111140500_R6","doi-asserted-by":"crossref","unstructured":"Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995\u20132001. Vaccine.\u20082004;22:4342\u20134350","DOI":"10.1016\/j.vaccine.2004.04.014"},{"key":"2023092514111140500_R7","doi-asserted-by":"crossref","unstructured":"Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA.\u20082005;294:202\u2013210","DOI":"10.1001\/jama.294.2.202"},{"key":"2023092514111140500_R8","unstructured":"Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082006;55(RR-7):1\u201323"},{"key":"2023092514111140500_R9","doi-asserted-by":"crossref","unstructured":"Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol.\u20081993;18(suppl 2):S11\u2013S14","DOI":"10.1016\/S0168-8278(05)80371-X"},{"key":"2023092514111140500_R10","doi-asserted-by":"crossref","unstructured":"Bowden FJ, Currie BJ, Miller NC, Locarnini SA, Krause VL. Should aboriginals in the \u201ctop end\u201d of the Northern Territory be vaccinated against hepatitis A?Med J Aust.\u20081994;161:372\u2013373","DOI":"10.5694\/j.1326-5377.1994.tb127490.x"},{"key":"2023092514111140500_R11","doi-asserted-by":"crossref","unstructured":"Martin DJ, Blackburn NK, Johnson S, McAnerney JM. The current epidemiology of hepatitis A infection in South Africa: implications for vaccination. Trans R Soc Trop Med Hyg.\u20081994;88:288\u2013291","DOI":"10.1016\/0035-9203(94)90080-9"},{"key":"2023092514111140500_R12","doi-asserted-by":"crossref","unstructured":"Shapiro CN, Coleman PJ, McQuillan GM, Alter MJ, Margolis HS. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine.\u20081992;10(suppl 1):S59\u2013S62","DOI":"10.1016\/0264-410X(92)90545-U"},{"key":"2023092514111140500_R13","unstructured":"Shapiro CN, Shaw FE, Mandel EJ, Hadler SC. Epidemiology of hepatitis A in the United States. In: Hollinger FB, Lemon SM, Margolis G, eds. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams & Wilkins Co; 1991:71\u201376"},{"key":"2023092514111140500_R14","doi-asserted-by":"crossref","unstructured":"Bialek SR, Thoroughman DA, Hu D, et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990\u20132001. Am J Public Health.\u20082004;94:996\u20131001","DOI":"10.2105\/AJPH.94.6.996"},{"key":"2023092514111140500_R15","doi-asserted-by":"crossref","unstructured":"Lemon SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang.\u20081994;67(suppl 4):19\u201323; discussion 24\u201326","DOI":"10.1159\/000462759"},{"key":"2023092514111140500_R16","doi-asserted-by":"crossref","unstructured":"Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion.\u20081998;38:573\u2013579","DOI":"10.1046\/j.1537-2995.1998.38698326337.x"},{"key":"2023092514111140500_R17","doi-asserted-by":"crossref","unstructured":"Benjamin RJ. Nucleic acid testing: update and applications. Semin Hematol.\u20082001;38(4 suppl 9):11\u201316","DOI":"10.1053\/shem.2001.28829"},{"key":"2023092514111140500_R18","doi-asserted-by":"crossref","unstructured":"Jackson LA, Stewart LK, Solomon SL, et al. Risk of infection with hepatitis A, B or C, cytomegalovirus, varicella or measles among child care providers. Pediatr Infect Dis J.\u20081996;15:584\u2013589","DOI":"10.1097\/00006454-199607000-00005"},{"key":"2023092514111140500_R19","doi-asserted-by":"crossref","unstructured":"Shapiro CN, Hadler SC. Hepatitis A and hepatitis B virus infections in day-care settings. Pediatr Ann.\u20081991;20:435\u2013441","DOI":"10.3928\/0090-4481-19910801-09"},{"key":"2023092514111140500_R20","doi-asserted-by":"crossref","unstructured":"Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis.\u20082004;38:705\u2013715","DOI":"10.1086\/381671"},{"key":"2023092514111140500_R21","doi-asserted-by":"crossref","unstructured":"Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States: implications for vaccination strategies. J Infect Dis.\u20081998;178:1579\u20131584","DOI":"10.1086\/314518"},{"key":"2023092514111140500_R22","doi-asserted-by":"crossref","unstructured":"Krugman S, Ward R, Giles JP, Bodansky O, Jacobs AM. Infectious hepatitis: detection of virus during the incubation period and in clinically inapparent infection. N Engl J Med.\u20081959;261:729\u2013734","DOI":"10.1056\/NEJM195910082611501"},{"key":"2023092514111140500_R23","doi-asserted-by":"crossref","unstructured":"Yotsuyanagi H, Koike K, Yasuda K, et al. Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology.\u20081996;24:10\u201313","DOI":"10.1053\/jhep.1996.v24.pm0008707246"},{"key":"2023092514111140500_R24","doi-asserted-by":"crossref","unstructured":"Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis.\u20081991;164:476\u2013482","DOI":"10.1093\/infdis\/164.3.476"},{"key":"2023092514111140500_R25","doi-asserted-by":"crossref","unstructured":"Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A: review of 14 cases and literature survey. Medicine (Baltimore).\u20081992;71:14\u201323","DOI":"10.1097\/00005792-199201000-00002"},{"key":"2023092514111140500_R26","doi-asserted-by":"crossref","unstructured":"Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med.\u20081987;106:221\u2013226","DOI":"10.7326\/0003-4819-106-2-221"},{"key":"2023092514111140500_R27","doi-asserted-by":"crossref","unstructured":"Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988\u20132004. Clin Infect Dis.\u20082006;42:490\u2013497","DOI":"10.1086\/499816"},{"key":"2023092514111140500_R28","doi-asserted-by":"crossref","unstructured":"Weinberg M, Hopkins J, Farrington L, Gresham L, Ginsberg M, Bell BP. Hepatitis A in Hispanic children who live along the United States-Mexico border: the role of international travel and food-borne exposures. Pediatrics.\u20082004;114(1). Available at: www.pediatrics.org\/cgi\/content\/full\/114\/1\/e68","DOI":"10.1542\/peds.114.1.e68"},{"key":"2023092514111140500_R29","doi-asserted-by":"crossref","unstructured":"Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol.\u20081985;122:226\u2013233","DOI":"10.1093\/oxfordjournals.aje.a114093"},{"key":"2023092514111140500_R30","doi-asserted-by":"crossref","unstructured":"Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis.\u20081986;8:548\u2013557","DOI":"10.1093\/clinids\/8.4.548"},{"key":"2023092514111140500_R31","unstructured":"Krugman S. Viral hepatitis: new clinical, epidemiological and immunological concepts. Calif Med.\u20081970;113:57\u201359"},{"key":"2023092514111140500_R32","doi-asserted-by":"crossref","unstructured":"Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine.\u20081992;10(suppl 1):S15\u2013S17","DOI":"10.1016\/0264-410X(92)90533-P"},{"key":"2023092514111140500_R33","unstructured":"Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams & Wilkins Co; 1991:76\u201378"},{"key":"2023092514111140500_R34","doi-asserted-by":"crossref","unstructured":"Leikin E, Lysikiewicz A, Garry D, Tejani N. Intrauterine transmission of hepatitis A virus. Obstet Gynecol.\u20081996;88(4 pt 2):690\u2013691","DOI":"10.1016\/0029-7844(96)00259-1"},{"key":"2023092514111140500_R35","doi-asserted-by":"crossref","unstructured":"McDuffie RS Jr, Bader T. Fetal meconium peritonitis after maternal hepatitis A. Am J Obstet Gynecol.\u20081999;180:1031\u20131032","DOI":"10.1016\/S0002-9378(99)70678-2"},{"key":"2023092514111140500_R36","doi-asserted-by":"crossref","unstructured":"Tong MJ, Thursby M, Rakela J, McPeak C, Edwards VM, Mosley JW. Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology.\u20081981;80:999\u20131004","DOI":"10.1016\/0016-5085(81)90072-X"},{"key":"2023092514111140500_R37","doi-asserted-by":"crossref","unstructured":"Watson JC, Fleming DW, Borella AJ, Olcott ES, Conrad RE, Baron RC. Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit. J Infect Dis.\u20081993;167:567\u2013571","DOI":"10.1093\/infdis\/167.3.567"},{"key":"2023092514111140500_R38","doi-asserted-by":"crossref","unstructured":"Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, Purcell RH. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis.\u20081986;154:231\u2013237","DOI":"10.1093\/infdis\/154.2.231"},{"key":"2023092514111140500_R39","doi-asserted-by":"crossref","unstructured":"Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis.\u20082000;182:12\u201317","DOI":"10.1086\/315701"},{"key":"2023092514111140500_R40","doi-asserted-by":"crossref","unstructured":"Cobden I, James OF. A biphasic illness associated with acute hepatitis A virus infection. J Hepatol.\u20081986;2:19\u201323","DOI":"10.1016\/S0168-8278(86)80004-6"},{"key":"2023092514111140500_R41","doi-asserted-by":"crossref","unstructured":"Tedeschi MV, Yoshida CF, Silva M, Feinstone SM. Detection of hepatitis A viral genome in stool samples of patients with relapsed hepatitis A by the polymerase chain reaction. Mem Inst Oswaldo Cruz.\u20081989;84:429","DOI":"10.1590\/S0074-02761989000300022"},{"key":"2023092514111140500_R42","doi-asserted-by":"crossref","unstructured":"Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine.\u20081992;10(suppl 1):S18\u2013S20","DOI":"10.1016\/0264-410X(92)90534-Q"},{"key":"2023092514111140500_R43","unstructured":"Lemon SM, Shapiro CN. The value of immunization against hepatitis A. Infect Agents Dis.\u20081994;3:38\u201349"},{"key":"2023092514111140500_R44","doi-asserted-by":"crossref","unstructured":"Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic?J Viral Hepat.\u20082000;7(suppl 1):1\u20133","DOI":"10.1046\/j.1365-2893.2000.00021.x"},{"key":"2023092514111140500_R45","doi-asserted-by":"crossref","unstructured":"Keeffe E. Hepatitis A in patients with chronic liver disease: severity of illness and prevention with vaccination. J Viral Hepat.\u20082000;7(suppl 1):15\u201317","DOI":"10.1046\/j.1365-2893.2000.00016.x"},{"key":"2023092514111140500_R46","doi-asserted-by":"crossref","unstructured":"Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med.\u20081998;338:286\u2013290","DOI":"10.1056\/NEJM199801293380503"},{"key":"2023092514111140500_R47","doi-asserted-by":"crossref","unstructured":"Debray D, Cullufi P, Devictor D, Fabre M, Bernard O. Liver failure in children with hepatitis A. Hepatology.\u20081997;26:1018\u20131022","DOI":"10.1002\/hep.510260433"},{"key":"2023092514111140500_R48","doi-asserted-by":"crossref","unstructured":"Shah U, Habib Z, Kleinman RE. Liver failure attributable to hepatitis A virus infection in a developing country. Pediatrics.\u20082000;105:436\u2013438","DOI":"10.1542\/peds.105.2.436"},{"key":"2023092514111140500_R49","unstructured":"Vaqta [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2006. Available at: www.merck.com\/product\/usa\/pi_circulars\/v\/vaqta\/vaqta_pi.pdf. Accessed November 10, 2006"},{"key":"2023092514111140500_R50","unstructured":"Havrix [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005. Available at: http:\/\/us.gsk.com\/products\/assets\/us_havrix.pdf. Accessed November 10, 2006"},{"key":"2023092514111140500_R51","doi-asserted-by":"crossref","unstructured":"Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine.\u20081992;10(suppl 1):S99\u2013S101","DOI":"10.1016\/0264-410X(92)90557-Z"},{"key":"2023092514111140500_R52","doi-asserted-by":"crossref","unstructured":"Ambrosch F, Andre FE, Delem A, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine.\u20081992;10(suppl 1):S142\u2013S145","DOI":"10.1016\/0264-410X(92)90570-A"},{"key":"2023092514111140500_R53","doi-asserted-by":"crossref","unstructured":"Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis.\u20081995;171(suppl 1):S44\u2013S49","DOI":"10.1093\/infdis\/171.Supplement_1.S44"},{"key":"2023092514111140500_R54","doi-asserted-by":"crossref","unstructured":"Usonis V, Meriste S, Bakasenas V, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12\u201318 months. Vaccine.\u20082005;23:2602\u20132606","DOI":"10.1016\/j.vaccine.2004.11.062"},{"key":"2023092514111140500_R55","doi-asserted-by":"crossref","unstructured":"Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, Lelie PN. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J Med Virol.\u20081993;40:22\u201327","DOI":"10.1002\/jmv.1890400106"},{"key":"2023092514111140500_R56","doi-asserted-by":"crossref","unstructured":"Cuthbert JA. Hepatitis A: old and new [erratum appears in Clin Microbiol Rev 2001;14:642]. Clin Microbiol Rev.\u20082001;14:38\u201358","DOI":"10.1128\/CMR.14.1.38-58.2001"},{"key":"2023092514111140500_R57","doi-asserted-by":"crossref","unstructured":"Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA.\u20081994;271:1328\u20131334","DOI":"10.1001\/jama.271.17.1328"},{"key":"2023092514111140500_R58","doi-asserted-by":"crossref","unstructured":"Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med.\u20081992;327:453\u2013457","DOI":"10.1056\/NEJM199208133270702"},{"key":"2023092514111140500_R59","doi-asserted-by":"crossref","unstructured":"Wiedermann G, Kundi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0\u20136 schedule). Acta Trop.\u20081998;69:121\u2013125","DOI":"10.1016\/S0001-706X(97)00120-4"},{"key":"2023092514111140500_R60","doi-asserted-by":"crossref","unstructured":"Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA.\u20082001;286:2968\u20132973","DOI":"10.1001\/jama.286.23.2968"},{"key":"2023092514111140500_R61","doi-asserted-by":"crossref","unstructured":"Domi\u0301nguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine.\u20082003;21:698\u2013701","DOI":"10.1016\/S0264-410X(02)00583-2"},{"key":"2023092514111140500_R62","doi-asserted-by":"crossref","unstructured":"Black S, Shinefield H, Hansen J, Lewis E, Su L, Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine.\u20082004;22:766\u2013772","DOI":"10.1016\/j.vaccine.2003.08.034"},{"key":"2023092514111140500_R63","doi-asserted-by":"crossref","unstructured":"Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics.\u20082007;119(1). Available at: www.pediatrics.org\/cgi\/content\/full\/119\/1\/e12","DOI":"10.1542\/peds.2006-1573"},{"key":"2023092514111140500_R64","doi-asserted-by":"crossref","unstructured":"Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J.\u20082003;22:904\u2013914","DOI":"10.1097\/01.inf.0000091295.53969.6a"},{"key":"2023092514111140500_R65","unstructured":"American Academy of Pediatrics. Vaccine administration. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006:18\u201322"},{"key":"2023092514111140500_R66","doi-asserted-by":"crossref","unstructured":"Williams JL, Bruden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine.\u20082003;21:3208\u20133211","DOI":"10.1016\/S0264-410X(03)00250-0"},{"key":"2023092514111140500_R67","doi-asserted-by":"crossref","unstructured":"Wiedermann G, Ambrosch F. Immunogenicity of an inactivated hepatitis A vaccine after exposure at 37 degrees C for 1 week. Vaccine.\u20081994;12:401\u2013402","DOI":"10.1016\/0264-410X(94)90113-9"},{"key":"2023092514111140500_R68","doi-asserted-by":"crossref","unstructured":"Connor BA, Phair J, Sack D, et al. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis.\u20082001;32:396\u2013401","DOI":"10.1086\/318522"},{"key":"2023092514111140500_R69","doi-asserted-by":"crossref","unstructured":"Bell BP, Kruszon-Moran D, Shapiro CN, Lambert SB, McQuillan GM, Margolis HS. Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine.\u20082005;23:5798\u20135806","DOI":"10.1016\/j.vaccine.2005.03.060"},{"key":"2023092514111140500_R70","doi-asserted-by":"crossref","unstructured":"Lopalco PL, Salleras L, Barbuti S, et al. Hepatitis A and B in children and adolescents: what can we learn from Puglia (Italy) and Catalonia (Spain)?Vaccine.\u20082000;19:470\u2013474","DOI":"10.1016\/S0264-410X(00)00193-6"},{"key":"2023092514111140500_R71","doi-asserted-by":"crossref","unstructured":"Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need?Lancet.\u20082003;362:1065\u20131071","DOI":"10.1016\/S0140-6736(03)14418-2"},{"key":"2023092514111140500_R72","doi-asserted-by":"crossref","unstructured":"Amon JJ, Darling N, Fiore AE, Bell BP, Barker LE. Factors associated with hepatitis A vaccination among children 24 to 35 months of age: United States, 2003. Pediatrics.\u20082006;117:30\u201333","DOI":"10.1542\/peds.2005-0286"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/189\/1531383\/zpe00707000189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/189\/1531383\/zpe00707000189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:11:47Z","timestamp":1695651107000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/120\/1\/189\/70548\/Hepatitis-A-Vaccine-Recommendations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,7,1]]},"published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1088","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}